FDA hits Neumora with clinical hold for schizophrenia drug after preclinical data showed convulsions in rabbits
Neumora Therapeutics has hit a road block to becoming a major neuroscience player, with the FDA placing a clinical hold on a Phase 1 study …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
